INTELLI-DESVENLAFAXINE TABLET (EXTENDED-RELEASE)
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
02-02-2022
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE)
から入手可能:
INTELLIPHARMACEUTICS CORP
ATCコード:
N06AX23
INN（国際名）:
DESVENLAFAXINE
投薬量:
50MG
医薬品形態:
TABLET (EXTENDED-RELEASE)
構図:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50MG
投与経路:
ORAL
パッケージ内のユニット:
14/100
処方タイプ:
Prescription
製品概要:
Active ingredient group (AIG) number: 0152509001; AHFS:
認証ステータス:
APPROVED
承認日:
2022-02-14
製品の特徴
PRODUCT MONOGRAPH
PR INTELLI-DESVENLAFAXINE
desvenlafaxine extended-release tablets
50 mg and 100 mg desvenlafaxine (as desvenlafaxine succinate
monohydrate
)
Antidepressant
Intellipharmaceutics Corp.
30 Worcester Road
Toronto, Ontario
Date of Revision:
February 2, 2022
Canada, M9W 5X2
Submission
Control No: 257079
_________________________________________________________________________________________
_Intelli-Desvenlafaxine (desvenlafaxine succinate monohydrate) Product
Monograph _
_Page 2 of 52_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFOR
M
ATION
..................................................................3
SUMMARY PRODUCT INFORMATION
.....................................................................................3
INDICATIONS AND CLINICAL USE
..........................................................................................3
CONTRAINDICATIONS
.............................................................................................................4
WARNINGS AND PRECAUTIONS
..............................................................................................4
ADVERSE REACTIONS
...........................................................................................................
11
DRUG INTERACTIONS
...........................................................................................................
21
DOSAGE AND ADMINISTRATION
..........................................................................................
24
OVERDOSAGE
........................................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
...........................................................................
28
STORAGE AND STABILITY
....................................................................................................
31
SPECIAL HANDLING INSTRUCTIONS
....................................................................................
31
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................
完全なドキュメントを読む
